Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dacomitinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 8/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | SRC | P12931 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | MC3R | P41968 | 1/20 | 0.98 |
| ▸ | JAK3 | P52333 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacomitinib Anhydrous SCHEMBL22498351 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29377744 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29445648 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL33136 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29377735 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL25098 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL33147 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL30115337 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29354322 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230398116-A1 | Agent for reversing resistance to anticancer drugs | Y'S AC CO., LTD. (JP) | 2023-12-14 | — | — | US | claimed |
| WO-2023230233-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2023-11-30 | — | — | WO | claimed |
| EP-4277616-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | Dyve Biosciences, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-4205126-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | Guardant Health, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| WO-2023101710-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | VERU INC. (US) | 2023-06-08 | — | — | WO | claimed |
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | VERU, INC. (US) | 2023-06-08 | — | — | US | claimed |
| US-20230173295-A1 | Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| EP-4186526-A1 | AGENT FOR REVERSING RESISTANCE TO ANTICANCER DRUGS | Y'S AC Co., Ltd. (JP) | 2023-05-31 | — | — | EP | claimed |
| CN-115379837-A | Transdermal formulations for drug administration | 黛芙生物科学公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220257552-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | VERU, INC. (US) | 2022-08-18 | — | — | US | claimed |
| WO-2022174121-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | VERU, INC. (US) | 2022-08-18 | — | — | WO | claimed |
| WO-2022155352-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| WO-2022046947-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | GUARDANT HEALTH, INC. (US) | 2022-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172897-A1 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | AR, CYP19A1, NR5A1 | EGFR 85/4885ERBB2 86/4885ERBB4 286/4885 |
| US-20220257552-A1 | METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | PGR, TTK, CDK6 | EGFR 20/4885ERBB2 15/4885ERBB4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.